DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Medplus Health Services Limited — Actions initiated/taken or orders passed-XBRL

NSE 1 hr ago·22 Aug 2026, 7:39 am

Medplus Health Serv

Medplus Health Services has informed exchanges about actions taken or orders passed by a regulatory body. The company filed an XBRL (eXtensible Business Reporting Language) submission detailing this development. This disclosure is a standard regulatory requirement that ensures transparency regarding any official proceedings or decisions affecting the business.

For investors, this news highlights the importance of monitoring corporate filings. While the specific nature of the action is not detailed in the headline, any regulatory intervention can impact a company's operations or reputation. It serves as a prompt for investors to review the full regulatory filing to understand the context and potential implications for the company's future performance.

Investors should watch for further official announcements from Medplus or the regulatory body. The company may provide more details in its future reports. Keeping an eye on how the management addresses the situation will be key to assessing its impact on the stock.